Journal article
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy
HCF Moore, JM Unger, KA Phillips, F Boyle, E Hitre, D Porter, PA Francis, LJ Goldstein, HL Gomez, CS Vallejos, AH Partridge, SR Dakhil, AA Garcia, J Gralow, JM Lombard, JF Forbes, S Martino, WE Barlow, CJ Fabian, L Minasian Show all
New England Journal of Medicine | Published : 2015
Abstract
BACKGROUND Ovarian failure is a common toxic effect of chemotherapy. Studies of the use of gonadotropin- releasing hormone (GnRH) agonists to protect ovarian function have shown mixed results and lack data on pregnancy outcomes. METHODS We randomly assigned 257 premenopausal women with operable hormone-receptor- negative breast cancer to receive standard chemotherapy with the GnRH agonist goserelin (goserelin group) or standard chemotherapy without goserelin (chemotherapy- alone group). The primary study end point was the rate of ovarian failure at 2 years, with ovarian failure defined as the absence of menses in the preceding 6 months and levels of follicle-stimulating hormone (FSH) in the ..
View full abstractRelated Projects (1)
Grants
Awarded by National Cancer Institute
Funding Acknowledgements
Funded by the National Cancer Institute and others; POEMS/S0230 ClinicalTrials.gov number, NCT00068601.